Fate Therapeutics (FATE) PT Raised to $40 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Fate Therapeutics (FATE) PT Raised to $45 at Guggenheim
June 10, 2020 7:51 AM EDTGuggenheim analyst Michael Schmidt raised the price target on Fate Therapeutics (NASDAQ: FATE) to $45.00 (from $43.00) while maintaining a Buy rating after the company provided a portfolio-wide clinical update. The update was part of the SEC filings for FATE's capital raise.
Guggenheim... More
Fate Therapeutics (FATE) Prices 6.18M Share Common Offering at $28.31/Sh
June 9, 2020 5:53 AM EDTFate Therapeutics, Inc. (NASDAQ: FATE) today announced the pricing of an underwritten public offering of 6,181,562 shares of its common stock at a public offering price of $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 927,234 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected... More
Fate Therapeutics (FATE) Commences Public Offering of Common Stock
June 8, 2020 4:03 PM EDTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction,... More
